How the EpiPen drug price story went viral — and what may be next

first_img Meghana Keshavan A mind-boggling price hikeMartin Shkreli’s 5,000 percent price hike for the drug daraprim, often used to treat infections in patients with AIDS, turned him into the poster boy for pharmaceutical greed. Mylan steadily hiked the price of the EpiPen year after year after year — often, twice a year, with no explanation other than that the market would bear it.Another company with this ingredient: Insulin makers. The cost for insulin has more than tripled since 2002 — despite the fact that improvements in insulin in the past decades have been merely incremental.A compelling patient storyThe very thought of an anaphylactic 7-year-old does tug at the heartstrings — and the prospect of such a child being unable to easily access an epinephrine auto-injector has clearly struck a nerve. Similarly, it wasn’t simply Shkreli’s bombast that incited the public. It was the fact that daraprim was used primarily in HIV patients — already a marginalized population.“We’re seeing increases all the time in drug prices — so the key here is whether the issue can excite an audience’s passion,” said Peter LaMotte, senior vice president of Chernoff Newman, a firm that works in crisis communications and reputation management. “For some companies, it blows up. For other companies, it goes completely under the radar.”Another company with this ingredient: Teva Pharmaceuticals has increased the price of multiple sclerosis drug Copaxone 118 percent since 2011, according to Reuters — despite competing with a generic form of this drug that’s been available since last year. Patients with MS must regularly imbibe a costly cocktail of medications to ward away the devastating symptoms of this disease.The Bernie Sanders factorWe’re in an election cycle, and the presidential candidates — particularly Hillary Clinton and former Democratic contender Bernie Sanders — have often made a punching bag of pharma. Sanders, in particular, has helped push along the drug pricing issue. He weighed in early, and critically, about Valeant Pharmaceuticals’s price hikes. He publicly rejected a campaign donation from Martin Shkreli. And just this week, he tweeted out (in reference to Mylan) that “something is very, very wrong when drug companies value their profits over the lives of customers.”Another company with this ingredient: Medivation, which was just purchased by Pfizer. Sanders just called it out for over-pricing its prostate cancer drug Xtandi, calling its $129,000 price tag — which is quadruple the cost of the drug in other countries — “unconscionable.” Alex Hogan/STAT What’s the recipe for a drug pricing controversy?The biopharmaceutical industry is under attack for its bafflingly complex pricing, and the target du jour is Mylan: The public and politicians are seething over the fact that the drug maker’s epinephrine injector, the EpiPen, has more than quintupled in cost since 2007. It now retails for more than $600 for a two-pack.But what’s so special about the EpiPen? And why has the anger suddenly gone viral?advertisement Related: Biotech Correspondent Meghana covers biotech and contributes to The Readout newsletter. Hillary Clinton, AMA urge EpiPen manufacturer to rein in ‘exorbitant’ costs Mylan may have violated antitrust law in its EpiPen sales to schools, legal experts say BusinessHow the EpiPen drug price story went viral — and what may be next NewslettersSign up for The Readout Your daily guide to what’s happening in biotech. By Meghana Keshavan Aug. 26, 2016 Reprints [email protected] About the Author Reprints Privacy Policy Talia Bronshtein/STAT Source: Elsevier Clinical Solutions’ Gold Standard Drug Database At Mylan, CEO Heather Bresch is also inviting uncomfortable scrutiny. The simple fact that her father is Senator Joe Manchin (D-W.Va.) makes her an easy target in some quarters. Then there’s the fact that her salary has been rising right along with EpiPen prices, up more than 600 percent since 2007. Last year, her compensation was $19 million.Another company with this ingredient: Vertex Pharmaceuticals CEO Jeff Leiden took in a salary of $36.6 million in 2015, though he did accept a 23 percent pay cut this year, to $28 million. The company’s not necessarily raising prices, but it is setting them sky-high to begin with, like the cystic fibrosis drug Orkambi, priced at $259,000 for a year’s worth of treatment. How does the EpiPen work?Volume 90%Press shift question mark to access a list of keyboard shortcutsKeyboard ShortcutsEnabledDisabledPlay/PauseSPACEIncrease Volume↑Decrease Volume↓Seek Forward→Seek Backward←Captions On/OffcFullscreen/Exit FullscreenfMute/UnmutemSeek %0-9 facebook twitter Email Linkhttps://www.statnews.com/2016/08/26/epipen-recipe-price-controversy/?jwsource=clCopied EmbedCopiedLive00:0001:5201:52  EpiPens can stop a body from going into overdrive when it’s exposed to an allergen. Alex Hogan, Hyacinth Epinado/STAT We, the mediaThe media — and we, at STAT, are complicit — fueled the fire of both Shkreli outrage and what we’ve (somewhat shamelessly) taken to calling EpiPendimonium.Other companies with this ingredient: Basically every drug company out there is increasing its drug pricing. The cost of generic tetracycline, for instance, climbed from 6 cents in 2013 to $4.60 in 2015. On the other end of the spectrum, earlier this year, Vanda Pharmaceuticals increased the cost of Hetlioz, a drug that treats a sleep disorder in blind people, up to $148,000 per year — a cost that’s 76 percent higher than it was in 2014.Occasionally, one case study catches fire and fuels a predictable cycle of media coverage, Twitter storms, online petitions, and congressional statements. What will be next? Use the comment field below to nominate your picks. Reports of the device’s price increases have circulated for years. And Mylan (like other drug makers) has been raising plenty of other prices, too: In recent years the list price for its gallstone drug ursodiol is up 542 percent, its irritable bowel syndrome drug dicyclomine is up 400 percent, and its antihypertensive drug verapamil has tripled in price.We’ve broken down the ingredients for a public uproar — and identified some other drug makers that may well find themselves in the hot seat next. To excite the public’s ire, there has to be:advertisement Leave this field empty if you’re human: A controversial CEO with a hefty paycheckShkreli’s general inability to keep quiet (and antics such as smirking his way through a congressional chastising) has made him a bit of an outlier compared to your standard chief executive. It was his personality, as much as the spiked cost of daraprim, that invited the outpouring of disgust. The rising cost of EpiPens050100150200250300350EpiPen inflation-adjusted (2016) list priceper 2-Pak in US dollarsDateEpiPen priceMay 16, 2016$304.31Nov 23, 2015$268.9May 1, 2015$234.03Nov 5, 2014$203.92May 2, 2014$177.47Nov 8, 2013$156.97Jul 17, 2013$136.62Nov 7, 2012$126.12Jul 27, 2012$114.76Mar 6, 2012$104.42Oct 18, 2011$96.98May 12, 2011$88.25Dec 15, 2010$82.84Aug 3, 2010$75.38Oct 12, 2009$69.71Jan 14, 2009$58.05Jan 16, 2008$55.09Feb 22, 2007$54.48Feb 23, 2006$53.88Feb 23, 2005$53.48Nov 1, 2004$53.16The rising cost of EpiPens Related: Please enter a valid email address. Tags EpiPenMylan @megkesh last_img read more

Continue Reading

2019 Nissan Altima shakes up the segment with standard AWD

first_img We encourage all readers to share their views on our articles using Facebook commenting Visit our FAQ page for more information. “When we look at how Altima is going to shake up the segment, all-wheel drive is a key element,” said José Muñoz, Nssan’s chief performance officer. “The lack of available all-wheel drive has also been a factor in buyers who prefer sedans switching to compact SUVs.”Nissan’s Intelligent AWD system uses an advanced torque split control strategy that automatically redistributes torque to the wheels — 0:100 biased towards the front all the way to a symmetrical, 50:50 split front-to-rear — according to driving conditions and wheel slippage. Said AWD system even works in conjunction with the Altima’s brake-based limited-slip differential and Hill Start Assist to manage those nerve-wracking takeoffs on steep, slippery hills. It is also worth noting that Nissan Canada sees powering all four wheels as an important differentiator in this hotly contested segment, “Altima with all-wheel-drive” a major part of its communications strategy.The torque all those subsystems are managing comes from a revised 2.5-litre four that now boasts 188 horsepower and 180 pound-feet, up from 179 HP and 177 lb.-ft. of torque, respectively, over the previous 2.5L engine. Created with Raphaël 2.1.2Created with Raphaël 2.1.22019 NIssan AltimaAndrew McCredie, Driving Created with Raphaël 2.1.2Created with Raphaël 2.1.22019 NIssan AltimaAndrew McCredie, Driving Created with Raphaël 2.1.2Created with Raphaël 2.1.2The 2019 NIssan Altima draws a crowd at the 2018 New York Auto Show. See? Automakers still care about sedans.Andrew McCredie, Driving Created with Raphaël 2.1.2Created with Raphaël 2.1.22019 NIssan AltimaAndrew McCredie, Driving Created with Raphaël 2.1.2Created with Raphaël 2.1.22019 NIssan AltimaAndrew McCredie, Driving Created with Raphaël 2.1.2Created with Raphaël 2.1.22019 NIssan AltimaAndrew McCredie, Driving Created with Raphaël 2.1.2Created with Raphaël 2.1.22019 NIssan AltimaAndrew McCredie, Driving Created with Raphaël 2.1.2Created with Raphaël 2.1.22019 NIssan AltimaAndrew McCredie, Driving RELATED TAGSAltimaNissanNew YorkNew York Auto ShowNews What is it? The all-new 2019 Altima is Nissan’s affirmation that the traditional family sedan segment is still vibrant.Why does it matter? The family sedan segment is shrinking, yet certain manufacturers — Toyota, Honda and now Nissan — are pouring huge resources into new products to invigorate what was once the dominant segment in passenger car sales.So, for 2019, Altima gets a more powerful engine, a host of semi-autonomous driver’s aids and, perhaps most importantly, all-wheel-drive across the entire model lineup in Canada. It is this last that Nissan sees stemming the onslaught of compact crossovers. Buy It! Princess Diana’s humble little 1981 Ford Escort is up for auction An engagement gift from Prince Charles, the car is being sold by a Princess Di “superfan” advertisement ‹ Previous Next › COMMENTSSHARE YOUR THOUGHTS “The development of the new 2.5-litre engine started with reviewing the basic specifications one by one. The result is an enhanced combination of high output and low fuel consumption versus the previous engine – with the bonus of improved NVH,” said Muñoz.It is worth noting that Americans will have access to a 2.0-litre variable compression inline-four turbo much like that powering Infiniti QX50. Unfortunately, since it is only available in front-wheel-drive guise, it will not be coming to Canada – at least not right now, says Nissan senior manager of product planning Bert Brooks. Nissan Canada is committed to offering AWD on all Altimas. All 2019 Altimas are also equipped with a standard Xtronic CVT transmission, which receives an expanded lock-up area for improved fuel efficiency.As for styling, the new Altima is much more aggressively styled than the previous version. According to Ken Lee, the fact that crossovers are now the mainstream is actually a good thing, Nissan’s global program design director saying it’s “now OK to make sedans with more personality.” So, the all-new Altima takes its inspiration from Nissan’s Vmotion 2.0 concept. Like the show car, the production Altima is lower, wider and longer than previous generations, and has shorter overhangs thanks to a 50-mm longer wheelbase. And, says Alfonso Albaisa, senior vice president, global design, “through clever packaging, we were able to push the hood and cowl downward, which combined with larger 19-inch wheels, really help the vehicle’s stance.”Last but not least, Altima gets Nissan’s latest ProPilot Assist semi-autonomous technology. The foundation for Nissan’s future autonomous vehicles, ProPilot Assist helps drivers stay centered in the lane, navigate stop-and-go traffic, maintain a set vehicle speed and maintain a set distance to the vehicle ahead all with two simple buttons – essentially, just activate the system with one button, then activate the Intelligent Cruise Control system.When is it coming? Fall 2019 Trending in Canada Full coverage of the 2018 New York Auto Show Created with Raphaël 2.1.2Created with Raphaël 2.1.2 2019 NIssan Altima Should you buy it? What’s not to like about a still-practical Altima with more power, all-wheel-drive, a bunch of high-tech safety system and aggressive styling. And don’t forget, much better fuel economy than a comparable SUV.RELATEDlast_img read more

Continue Reading

Chase Elliott’s runner-up finish a ‘huge step in the right direction’

first_imgRELATED: Race results | Playoff standingsJOLIET, Ill. – If it hadn’t been for Martin Truex Jr., Chase Elliott might have been hoisting his first Monster Energy NASCAR Cup Series trophy into the air — and getting covered in green slime — following Sunday’s NASCAR Playoffs opener at Chicagoland Speedway.But for the No. 24 driver, a runner-up finish, one that may have dampened his mood last year during his rookie season, does more than just earn race points.Elliott called it a “huge step in the right direction.”“Days like this are the days we’re going to have to have,” he said. “There’s no way around that. So, I thought we had a solid day overall … and frankly it’s a lot better than we’ve been doing and we’ve got to have days like this moving forward.”Having led 42 laps in Sunday’s 400-miler was a feat in itself for the No. 24 driver, who hasn’t paced the field for more than 20 laps since Phoenix back in March. In fact, his 42-lap total today was more than his entire laps-led total since then.Call it a much-needed shot in the arm.“To me, I think we all needed it; we all needed the realization that if we do have the car driving right, if we do have the right pit stops on pit road, restarts go good, we can run with those guys,” Elliott said. “We didn’t have anything for (race winner) Martin (Truex Jr.) today by any means but I thought we made the most with what we had. I thought we were better than about everybody else.“To me, I think that’s something to be proud of.”RELATED: Analyzing the playoff fieldCrew chief Alan Gustafson echoed that sentiment later in the garage.“Any time you can lead laps and compete with the best of the best, it’s a big deal,” Gustafson said. “So, I think it’s good for his confidence. I have confidence in the team and what we can accomplish. … I think it’s good for him. Any time you perform like that, you know you can do it.Winning Stage 2 — which earned Elliott a valuable playoff point and 10 race points — certainly didn’t hurt either.“Those stage points we gained today – those were really significant, that was a goal of ours,” Gustafson said. “Starting the race, we wanted to get as many stage points as we could and that would help us close the gap on those guys who had a pretty big bonus point advantage. …“The one stage point isn’t going to hurt – we’ll take it. I’d like to have five more — unfortunately the 78 didn’t cooperate,” he joked.Team owner Rick Hendrick paid a visit to the No. 24 car after the race to congratulate his young driver’s strong performance, one that comes just in time for the remaining nine-race NASCAR Playoffs stretch.“If you’re going to get hot or fix things or take a step in the right direction, now is certainly the time to do it,” Elliott said. “So, I’m glad we had the run we did today. Like I said, we needed that – we all needed that and we haven’t been running to our potential each week. It’s just always nice to show up and know that if things are driving right, if pit stops are good, then you can run with them.“And I think we just kind of proved to ourselves and everybody else that we can.”last_img read more

Continue Reading

Permatex Names Daniel Clarke As Senior Product Manager

first_imgWith more than 20 years of experience across multiple industries and functional areas, deMoulpied has particular expertise in organizations with complex technical products. Combined, his prior positions have required a spectrum of skills in corporate strategy, operations improvement, product quality, and revenue cycle management. He has an impressive history of utilizing data driven problem solving (Lean Six Sigma) and project management (PMP and CSM) to achieve strategic goals surrounding customer satisfaction, operational efficiency and improved profit.  DeMoulpied comes to LSI from the Private Client Services practice of Ernst & Young where he managed strategy & operations improvement engagements for privately held client businesses. Some of his prior roles include VP of strategic development, director of strategic initiatives, and Lean Six Sigma Master Black Belt at OptumHealth, UnitedHealth Group’s health services business, as well as Lean Six Sigma Black Belt at General Electric, where he applied operations improvement principles to customer service, supply chain and product development. A successful entrepreneur, deMoulpied is also the founder of PrestoFresh, a Cleveland-based e-commerce food/grocery business.  DeMoulpied has a Bachelor of Science degree in Engineering Management from the United States Air Force Academy and a Master of Business Administration degree from the University of Dayton in Marketing and International Business. He served six years with the USAF overseeing the development of technology used on fighter aircraft and the E-3 Surveillance aircraft, finishing his career honorably as Captain. Permatex, a leading innovator in chemical technology for automotive maintenance and repair, has named Daniel Clarke as senior product manager. Clarke’s responsibilities include management of a select product group marketed domestically and internationally, with a strong focus on new product development. He also will lead in the commercialization of new products and manage activities affecting profitability, including product life cycle management and cost-savings projects.AdvertisementClick Here to Read MoreAdvertisementThe announcement was made by Permatex’s Director of Marketing and Product Management, Sean Lyon, who noted, “Permatex is very excited to have Daniel Clarke join our team. His experience in supply chain management, market research and product line expansion will certainly be a major asset to our company.”Before joining Permatex, Clarke was a business unit manager at Coburn Technologies Inc., a South Windsor, Connecticut-based manufacturer of computer-integrated ophthalmic lens processing systems. In this role, he supervised the supply chain, production, sales, marketing and e-commerce for the business. Clarke also was responsible for increasing market share, improving production efficiency, increasing revenue and improving and updating the product offerings.Clarke holds a bachelor of science degree in business management from Albertus Magnus, and is currently pursuing a Masters of Business Administration from The University of Hartford Barney School of Business.,Lubrication Specialties Inc. (LSI), manufacturer of Hot Shot’s Secret brand of performance additives and oils, recently announced the expansion of senior leadership. Steve deMoulpied joins LSI as the company’s chief operating officer (COO). AdvertisementClick Here to Read MoreAdvertisement LSI President Brett Tennar says, “Steve’s success in developing operational strategies that improves the bottom line, builds teamwork, reduces waste and ensures quality product development and distribution checks many of the boxes of what we were looking for in a COO. This, coupled with his career in the Air Force working with highly technical systems and his in-depth understanding of Lean Six Sigma and Business Process Management sealed our offer. As our tagline states, our products are Powered by Science. This data driven approach is one reason why our company has grown exponentially as we employ the most advanced technology to product development. I am confident that Steve is the right person to drive operational strategy for our diverse and growing brands.” Advertisementlast_img read more

Continue Reading

NFL Week 2 Power Rankings

first_img3. CAROLINA PANTHERS 1-1 ⇔Last Week: 3rdCam Newton did not waste much time against the 49er’s after week one’s close loss to Denver. Throwing for over 350 yards and 4 TD’s is a notable feat, and one of the reason’s this team will be staying within the Top 5 on our list through-out the year. (Tune in next-week for more non-bold predictions.) 2. PITTSBURGH STEELERS 2-0 ⇑Last Week: 6thLeading all the running back candidates for most amount of touches in Week 2 is none other than DeAngelo Williams – 32 carries & 4 catches. The savvy veteran helped projectile the Steelers into the number two spot on our list and Mike Tomlin will have some tough decisions to make come Week 4 when Le’Veon Bell is scheduled to return. The NFL is scheduled to have a double dose of rookie QB debuts following some key injuries. Cody Kessler will get a chance to build some chemistry in practice leading into Week 3 and Jacoby Brissett will lead the Brady-less Bunch in New England for a few weeks. 5. ARIZONA CARDINALS 1-1 ⇑Last Week: 8thNew faces in the Top 5 this week as the air-show was in full affect this past week when Carson Palmer strapped his helmet up. Ending with a QB rating of 124.1 and throwing 4 TD’s, the Cardinals had Tampa Bay playing catch-up for the most part of this game. Even the back-up, Drew Stanton, was able to throw a couple passes in the latter stages. Pages: 1 2 3 4 5 6 7 Related TopicsBrownsNFLNFL Power Rankings 4. NEW ENGLAND PATRIOTS 2-0 ⇓Last Week: 2ndIn last week’s edition of our power rankings I set the guidelines for how our teams would be ranked this year; this would fall under the injury category. The two-spot descent is only a direct correlation Gorapollo’s early exit. However, the short turnaround could work in QB Jacoby Brissett’s favor but the Texans will be coming with full steam ahead on Thursday night. Week 2 NFL Power Rankingscenter_img 1. DENVER BRONCOS 2-0 ⇔Last Week: 1stDefense wins championships. No one will preach this more often than your everyday Broncos fan. This past week the Colts’ comeback chances were whisked away after a strip sack via Von Miller left the ball bouncing into Shane Ray’s awaiting hands for a scoop-and-score. The QB graveyard grew a bit larger this past week after some injuries to the luxury position caused some back-ups to dust off their helmets. Exclusively, Jimmy Garopollo and Josh McCown headline the tombstones this week. However, the Patriots find themselves in a much better position going forward with a first ballot hall of fame signal caller returning week five to play the Browns. Vince Miller Born and raised in Cleveland, Vince Miller has a strong passion for North East Ohio sports. A graduate of Medina High School and alumni of The Ohio Center for Broadcasting, Vince is in pursuit of a degree in sports journalism. While attending OCB he was awarded the opportunity to cover the Cavaliers and Indians, recording and editing audio from post-game interviews given by players and coaches. Give him a follow on Twitter @VinceMillerCLE and join in on some sports conversation!last_img read more

Continue Reading